2026年9月1日-11日，全球医药市场共签署了30项资产授权和合作协议。中国市场共达成8项交易，包括2项出海交易、2项引进交易和4项国内交易。
中国市场，本周最大的出海交易是和黄医药与GSK就临床一期资产HMPL-A830达成独家开发及许可协议，首付款1.1亿美元，总金额可达13亿美元。
中国以外市场，本周共签署了22项资产授权和合作协议。最大的交易是Pfizer授予Medicus Pharma临床早期ADC资产CD228V (PF-08046031)的全球开发、生产与商业化许可权益，首付款1200万美元，以及累计超过10亿美元的潜在里程碑付款。
From September 1 to 11, a total of 30 biopharmaceutical licensing and collaboration transactions were announced globally. Of these, eight were China-related, defined as transactions involving at least one China-based company. These comprised two out-licensing deals, two in-licensing deals and four domestic partnerships.
In China, the largest transaction involved Hutchison China MediTech and GSK for the Phase I HMPL-A830 asset, with an upfront payment of $110 million and a total deal value of $1.3 billion.
Outside China, 22 deals were announced. The largest transaction involved Medicus Pharma and Pfizer for CD228V (PF-08046031), an early clinical-stage antibody-drug conjugate, with an upfront payment of $12 million and aggregate potential development, regulatory, and sales milestone payments exceeding $1.0 billion.
3. M&A Deals
4. Top Deals of 2026
